You are here
Proof-of-Concept Phase 2 Study of Icatibant Concludes With Positive Results
"With Icatibant, we can help patients suffering from hereditary angioedema", stated Jens Schneider-Mergener, CEO of Jerini. He added that the subcutaneous formulation creates an enormous benefit for patients and will significantly improve the quality of life for patients suffering from HAE.
About Hereditary Angioedema
Hereditary angioedema (HAE) is a debilitating and life-threatening disease characterized by recurrent local swelling at three main sites: subcutaneous tissue, gastrointestinal tract, and larynx. In case of an attack affecting the airway passages, HAE is life threatening. Abdominal attacks are often associated with bouts of severe pain, nausea, and vomiting caused by swelling in the intestinal wall. The prevalence of HAE is believed to be between 1/10,000 and 1/50,000 people worldwide. Hereditary angioedema is caused by an activation of the kinin system leading to elevated bradykinin levels in the affected areas.
Icatibant is a potent and specific peptidomimetic bradykinin B2 receptor antagonist. Icatibant has exhibited an excellent safety profile in over 850 subjects. Icatibant is tested in clinical trials for treatment of hereditary angioedema and refractory ascites in liver cirrhosis as well as in preclinical models for severe burn injuries.
Source: Jerini AG